SCHEMBL10247192

SCHEMBL10247192

Cc1ccc(CCC(O)CCl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
CYP2A6 P11509 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
IGF1R P08069 1/20 0.43
ALOX15 P16050 1/20 0.43
PTGFR P43088 1/20 0.40
MMP12 P39900 4/20 0.39
MMP13 P45452 4/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP14 P50281 1/20 0.39
STAT3 P40763 1/20 0.39
DPP4 P27487 1/20 0.37
IDO1 P14902 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
KCNH2 Q12809 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HRH1 P35367 1/20 0.36
FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27325037 0.87 CYP1A2 (0.50) CYP1A2CYP2A6TAAR1IGF1RALOX15
SCHEMBL19321712 0.82 CYP1A2 (0.45) CYP1A2CYP2A6TAAR1IGF1RALOX15
SCHEMBL11471420 0.82 CYP1A2 (0.45) CYP1A2CYP2A6TAAR1IGF1RALOX15
SCHEMBL19321715 0.82 CYP1A2 (0.45) CYP1A2CYP2A6TAAR1IGF1RALOX15
SCHEMBL108916 0.82 CYP1A2 (0.45) CYP1A2CYP2A6TAAR1IGF1RALOX15
SCHEMBL409924 0.82 TAAR1 (0.45) CYP1A2TAAR1IGF1RALOX15MMP12
SCHEMBL4258881 0.80 CYP1A2 (0.43) CYP1A2CYP2A6TAAR1IGF1RALOX15
SCHEMBL408931 0.80 TAAR1 (0.43) TAAR1PTGFRMMP12MMP13MMP2
SCHEMBL1462321 0.80 CYP1A2 (0.43) CYP1A2CYP2A6TAAR1IGF1RALOX15
SCHEMBL18063343 0.80 TDP1 (0.51) PTGFRMMP12MMP13MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-8513294-B2 Substituted imidazole derivatives and methods of use thereof for treating cancer OSTA BIOTECHNOLOGIES (CA) 2013-08-20 US disclosed
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEENS UNIVERSITY AT KINGSTON (CA) 2012-01-26 US disclosed
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2011-12-29 US disclosed
US-7943650-B2 Methods of treating cancer with imidazolyl compounds OSTA BIOTECHNOLOGIES (CA) 2011-05-17 US disclosed
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2009-07-09 US disclosed
EP-0005980-B1 DERIVATIVES OF SUBSTITUTED N-ALKYL IMIDAZOLES, THEIR PREPARATION AND THESE COMPOUNDS FOR PHARMACEUTICAL USE SYNTEX (U.S.A.) INC. (US) 1984-08-29 EP disclosed
US-4272545-A FUNGICIDES, BACTERICIDE, ANTIPROTOZOA, SPERMATOCIDE SYNTEX (U.S.A.) INC. (US) 1981-06-09 US disclosed
US-4213991-A BACTERICIDES, FUNGICIDES, ANTIPROTOZOA SYNTEX (U.S.A.) INC. (US) 1980-07-22 US disclosed
EP-0005980-A2 Derivatives of substituted N-alkyl imidazoles, their preparation and these compounds for pharmaceutical use SYNTEX (U.S.A.) INC. (US) 1979-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System TXNRD2, HMOX1, HMOX2 CYP1A2 697/4885CYP2A6 1552/4885TAAR1 1059/4885
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 CYP1A2 629/4885CYP2A6 863/4885TAAR1 2422/4885
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 CYP1A2 629/4885CYP2A6 863/4885TAAR1 2422/4885
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 CYP1A2 764/4885CYP2A6 924/4885TAAR1 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.